Several other research firms have also recently weighed in on ADHD. WBB Securities cut Alcobra from a hold rating to a sell rating and decreased their target price for the stock from $5.00 to $4.00 in a research note on Monday, September 12th. Jefferies Group restated a buy rating on shares of Alcobra in a research note on Thursday, August 25th. Cantor Fitzgerald restated a buy rating and set a $16.00 target price on shares of Alcobra in a research note on Wednesday, August 31st. Goldman Sachs Group Inc. restated a buy rating on shares of Alcobra in a research note on Thursday, September 1st. Finally, Piper Jaffray Cos. restated an overweight rating and set a $10.00 target price on shares of Alcobra in a research note on Tuesday, August 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $6.47.
Alcobra (NASDAQ:ADHD) opened at 2.60 on Thursday. The firm has a 50-day moving average price of $4.62 and a 200-day moving average price of $4.50. Alcobra has a one year low of $1.95 and a one year high of $8.78. The firm’s market capitalization is $71.66 million.
Alcobra (NASDAQ:ADHD) last announced its quarterly earnings data on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. Equities analysts anticipate that Alcobra will post ($0.94) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADHD. Stifel Financial Corp raised its position in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares during the period. Palo Alto Investors LLC raised its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the period. VHCP Management LLC raised its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the period. VHCP Management II LLC raised its position in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock valued at $6,530,000 after buying an additional 323,902 shares during the period. Finally, Jefferies Group LLC bought a new position in Alcobra during the second quarter worth about $533,000. 73.69% of the stock is currently owned by institutional investors.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.